Association between soluble immune mediators and outcomes in patients with unresectable stage III non-small cell lung cancer treated with concurrent chemoradiotherapy followed by durvalumab.
- DOI
- 10.21037/tlcr-2025-563
- Published
- 2025 Oct 31
- Container
- Translational lung cancer research
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.21037/tlcr-2025-563,
title = {Association between soluble immune mediators and outcomes in patients with unresectable stage III non-small cell lung cancer treated with concurrent chemoradiotherapy followed by durvalumab.},
author = {Tokito T and Azuma K and Murotani K and Matsuo N and Matama G and Murata D and Sasada T and Hoshino T},
year = {2025},
journal = {Translational lung cancer research},
doi = {10.21037/tlcr-2025-563},
url = {https://doi.org/10.21037/tlcr-2025-563}
}RIS
TY - JOUR TI - Association between soluble immune mediators and outcomes in patients with unresectable stage III non-small cell lung cancer treated with concurrent chemoradiotherapy followed by durvalumab. AU - Tokito T AU - Azuma K AU - Murotani K AU - Matsuo N AU - Matama G AU - Murata D AU - Sasada T AU - Hoshino T PY - 2025 JO - Translational lung cancer research DO - 10.21037/tlcr-2025-563 UR - https://doi.org/10.21037/tlcr-2025-563 ER -
APA
T, T., K, A., K, M., N, M., G, M., D, M., T, S., & T, H. (2025). Association between soluble immune mediators and outcomes in patients with unresectable stage III non-small cell lung cancer treated with concurrent chemoradiotherapy followed by durvalumab.. Translational lung cancer research. https://doi.org/10.21037/tlcr-2025-563
Source records
- pubmed · retrieved 2026-09-26T03:23:08.104Z